Poster Presentations: Tuesday, November 2, 2010 |

Pharmacokinetic (PK) and Pharmacodynamic (PD) Modeling and Simulation Support the Novelty of MN-221, a Highly Selective Beta2-Adrenergic Receptor Agonist for Treatment of Acute Asthma FREE TO VIEW

Brian M. Sadler, PhD; Alan W. Dunton, MD; Maria Feldman, MS; Kazuko Matsuda, MD; James Bosley, PhD; Ron Beaver, PhD
Author and Funding Information

ROSA and Co., LLC, San Carlos, CA

Chest. 2010;138(4_MeetingAbstracts):168A. doi:10.1378/chest.10074
Text Size: A A A
Published online


PURPOSE: Health and economic impacts indicate the need for better treatments for acute asthma. To develop new therapies several issues must be understood including separating the effects of the trial therapy from standard of care (SOC) , non-responders in the trial, and variability in the efficacy (e.g. FEV1). To advance development of MN-221, a combined model of its population PK/PD was created to predict outcomes in patients.

METHODS: Data from two clinical trials in mild to moderate asthma patients were used to characterize the population PK/PD of MN- 221. It was extended using in vitro data and physiologic reasoning to represent the effects of MN-221 in combination therapy with albuterol.

RESULTS: The PK of MN-221 was characterized by a 3-compartment model in contrast to commonly used beta agonists. PD effects for heart rate and QTc were driven by MN-221 in plasma while FEV1 was driven from a separate compartment - again unique for beta 2 agonists. The combined models provided a solid basis for selecting safe and effective doses of MN-221 in acute patient trials and support its novel properties. The models accurately predicted trial outcomes, and helped determine appropriate sample sizes.

CONCLUSION: MN-221 has a unique PK/PD profile which supports its utility in optimally treating asthma exacerbations. Modeling: 1) enabled the use of patient data to predict the effect of MN 221 in acute patients, 2) supported dosing decisions, 3) predicted the impact of non-responders on trial outcome, and 4) suggested means and mechanisms for optimizing MN 221 treatment in combination with SOC.

CLINICAL IMPLICATIONS: MN-221 is a novel, differentiated beta 2 agonist. Further development is warranted as a new treatment for acute asthma.

DISCLOSURE: James Bosley, Shareholder Dunton, Feldman and Matsuda are shareholders of MediciNova, Inc.; Employee Dunton, Feldman and Matsuda are employees or consultants of MediciNova, Inc; Consultant fee, speaker bureau, advisory committee, etc. Sadler, Bosley and Beaver are paid consultants of MediciNova, Inc.; Product/procedure/technique that is considered research and is NOT yet approved for any purpose. MN-221 is a new beta adrenoreceptor agonist under development by MediciNova, Inc.

12:45 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543